Valuation : Nutra Pharma Corp.

Market Cap 716K 617K 584K 529K 993K 68.4M 998K 6.94M 2.67M 34.8M 2.69M 2.63M 110M P/E 2024
-0.6x
P/E 2025 -0.38x
Enterprise Value 12.04M 10.37M 9.82M 8.9M 16.7M 1.15B 16.78M 117M 44.85M 585M 45.21M 44.22M 1.85B EV / Sales 2024
27.1x
EV / Sales 2025 31.2x
Free-Float
98.98%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 2001-10-31
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 64 2016-07-26
Director TitleAgeSince
Director/Board Member 68 2009-07-28
Director/Board Member 78 2004-11-04
Director/Board Member 56 2001-10-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.22%-14.56%-5.64% 13.4B
-1.27%-3.07%-33.48%-56.88% 4.78B
-0.61%-5.58%-5.83%-6.20% 4.36B
-1.49%-4.28%-11.69%-32.46% 3.78B
-1.37%-3.98%-25.66%+0.79% 3.43B
-2.78%-3.65%-4.32%-5.13% 3.41B
-0.85%-4.82%-13.72%+3.39% 3.12B
-1.30%-2.63%-24.61%-18.99% 2.27B
-2.13%-2.81%-29.80%-20.08% 1.63B
Average -1.31%-2.87%-18.19%-15.69% 4.47B
Weighted average by Cap. -0.94%-2.27%-16.80%-14.37%

Financials

2024 2025
Net sales 392K 338K 320K 290K 544K 37.46M 547K 3.8M 1.46M 19.06M 1.47M 1.44M 60.23M 385K 332K 314K 285K 535K 36.81M 537K 3.73M 1.44M 18.73M 1.45M 1.42M 59.18M
Net income -1.29M -1.11M -1.05M -951K -1.78M -123M -1.79M -12.46M -4.79M -62.49M -4.83M -4.72M -197M -2.05M -1.76M -1.67M -1.51M -2.84M -196M -2.85M -19.84M -7.63M -99.51M -7.69M -7.52M -314M
Net Debt 9.91M 8.54M 8.08M 7.33M 13.75M 947M 13.82M 96.01M 36.92M 482M 37.21M 36.4M 1.52B 11.32M 9.76M 9.24M 8.37M 15.71M 1.08B 15.79M 110M 42.19M 550M 42.52M 41.59M 1.74B
Logo Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company's drug candidates include RPI-MN and RPI-78M. RPI-MN is used to treat neurological diseases and autoimmune diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), Rheumatoid Arthritis (RA) and Myasthenia Gravis. The RPI-78M is used to treat viral diseases, including HIV/AIDS and Herpes. The Company offers Nyloxin/Nyloxin Extra Strength as its over-the-counter (OTC) pain reliever. It is focused upon marketing homeopathic drugs for the treatment of pain: Nyloxin, Nyloxin Extra Strength Pet Pain, Equine Pain, and Luxury Feet.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!